Belrise Industries IPO Allotment: The Belrise Industries IPO allotment process has captured the attention of investors across India, following an overwhelming response to its ₹2,150 crore public issue. Drawing more than 25.35 lakh applications, the IPO has turned into one of the most closely watched listings in recent months. With an oversubscription of 41.30 times, this offering has significantly exceeded expectations, leading market participants to keenly track the allotment outcome, grey market premium (GMP), and listing prospects.
The Pune-based automotive component manufacturer opened its IPO from May 21 to May 23, offering shares at a fixed price band of ₹85–₹90 per equity share. The issue was entirely a fresh equity sale of 23.89 crore shares, aiming to fund business expansion and reduce debt. With the bidding now concluded, here’s an in-depth look at allotment probabilities, GMP developments, and next steps for investors.
Belrise Industries IPO Allotment: How to Check Allotment Status?
✅ Check Belrise Industris IPO Allotment: Via BSE Website:
- Visit https://www.bseindia.com/investors/appli_check.aspx
- Select ‘Equity’ as issue type
- Choose ‘Belrise Industries Limited‘ from the dropdown
- Enter PAN or application number
- Complete the CAPTCHA and click on ‘Search‘
✅Check Belrise Industris IPO Allotment: Via Link Intime (Registrar):
- Go to https://linkintime.co.in/initial_offer/public-issues.html
- Select ‘Belrise Industries Limited‘ from the dropdown
- Choose search option: PAN, Application Number, or DP ID
- Fill in details and click on ‘Search‘
These steps will allow you to access your allotment status and track further updates.
Also Read: The Leela Hotels IPO
Grey Market Premium Update: A Strong Signal
The latest GMP (Grey Market Premium) for Belrise Industries IPO stands at ₹25 per share, indicating that the stock is trading around ₹115 in the unlisted space. This represents a 28% premium over the issue price of ₹90, showcasing robust secondary market sentiment.
The consistent rise in GMP post-issue suggests strong listing expectations, backed by solid fundamentals, credible institutional interest, and positive market conditions. GMP is often used as a barometer of expected listing performance, though it is not a guaranteed outcome.
IPO Subscription Analysis: Who Stands a Better Chance?
The issue witnessed stellar participation across all investor categories:
-
- Qualified Institutional Buyers (QIBs): Subscribed 108.35 times
- Non-Institutional Investors (NIIs): Subscribed 38.33 times
- Retail Individual Investors (RIIs): Subscribed 4.27 times
Based on these figures, the estimated allotment chances are as follows:
- Retail Investors: 1 out of 4 applicants may receive 166 shares (Approx. 25% success rate)
- Small HNIs: 1 out of 25 applicants may get 2,324 shares (Approx. 4% chance)
- Big HNIs: 1 out of 10 applicants may receive 2,324 shares (Approx. 10% chance)
While the high oversubscription limits the chances of allotment, retail investors enjoy relatively better odds compared to HNI segments. These figures, however, are indicative and actual allotments may vary slightly.
Also Read: Borana Weaves IPO Allotment Out: Check Status, Latest GMP, Refund, and Listing Details
Summary of Belrise Industries IPO Details
- Company: Belrise Industries Ltd
- IPO Size: ₹2,150 crore (Fresh Issue only)
- Price Band: ₹85–₹90 per share
- Lot Size: 166 shares
- Overall Subscription: 41.30x
- Lead Managers: Axis Capital, Jefferies India, HSBC Securities, SBI Capital
- Registrar: Link Intime India Pvt Ltd
- Expected Listing: May 28, 2025, on NSE and BSE
Final Thoughts:
The Belrise Industries IPO stands out as a highly anticipated issue, driven by strong institutional support and optimistic market trends. With the allotment date nearing, retail investors are encouraged to check their status promptly and prepare for listing day. The rising GMP and solid fundamentals suggest a promising debut—but as always, market conditions will have the final say.
Disclaimer: The views and investment insights provided here are based on publicly available information and do not constitute financial advice. Readers are advised to conduct their own research or consult certified financial experts before making investment decisions.
